GLENN R. LARSEN, PH.D. - Corporate Board Profile

Anika Therapeutics, Inc.

Filing Date	Source Excerpt
2015-04-23	Glenn R. Larsen, Ph.D., joined the Board of Directors in February 2015. He is a co-founder and Chairman of the Board of Directors of 180 Therapeutics L.P. He has a strong scientific background and extensive experience in management and product development. The current members of the Compensation Committee include Dr. Larsen, who joined effective February 18, 2015. The Governance and Nominating Committee also includes Dr. Larsen, who joined effective February 18, 2015. The following table summarizes the compensation we paid to non-employee directors for the year ended December 31, 2014. Glenn R. Larsen: Stock Awards $59,973.
2016-04-20	Glenn R. Larsen, Ph.D., joined the Board of Directors in February 2015. He serves on the Compensation Committee and the Governance and Nominating Committee. For 2015, he received $32,211 in cash fees (pro-rated) and $89,973 in stock awards, totaling $122,184.
2017-04-28	Glenn R. Larsen, Ph.D., joined the Board of Directors in February 2015. He is currently President and Chief Executive Officer of Aquinnah Pharmaceuticals, Inc., a pharmaceutical company focused on the development of treatments for ALS and neurodegenerative diseases, which he co-founded in February 2014. He is also a co-founder and Chairman of the Board of Directors of 180 Therapeutics L.P., a clinical stage musculoskeletal drug development company focusing on treating fibrosis, which he co-founded in 2013. He previously served as Chief Scientific Officer and Executive Vice President of Research and Development at SpringLeaf Therapeutics, Inc., a producer of combination drug delivery devices, from 2010 through 2013 and as Chief Operating Officer and Executive Vice President of Research and Development, and as a member of the board of directors, at Hydra Biosciences, Inc., a biopharmaceutical company, from 2003 through 2010. During his prior employment at Wyeth (now Pfizer)/Genetics Institute, Dr. Larsen served in various drug discovery and development leadership positions, including Vice President Musculoskeletal Sciences where he directed Wyeth’s second-largest therapeutic area with responsibility for Enbrel, an anti-TNF therapeutic with multi-billion dollar annual sales used to treat rheumatoid arthritis and other diseases. Dr. Larsen received his Ph.D. in Biochemistry from Stony Brook University and a PMD from Harvard University Business School. Dr. Larsen’s qualifications for membership on the Board include his strong scientific background in pharmaceuticals, biotech, orthopedics, and regenerative medicine, and his extensive experience in management, product development, and business development at multiple companies in the life science industry, all of which provide the Board of Directors with innovative product and commercial development perspectives and insights. He serves as a member of the Compensation Committee and a member of the Governance and Nominating Committee.
2018-04-17	Glenn R. Larsen joined the Board in February 2015. He serves as a member of the Compensation Committee and a member of the Governance and Nominating Committee. The following table summarizes the compensation we paid to non-employee directors for 2017. Glenn R. Larsen: Fees Earned or Paid in Cash ($) 52,000, Stock Awards ($) 99,959, Total ($) 151,959.
2020-04-29	Glenn R. Larsen, Ph.D. Age: 65 Director since 2015 Committees: Compensation, Governance and Nominating 2019 Director Compensation: $187,480 Independent Director
2021-04-30	Glenn R. Larsen, Ph.D. Age: 67 Director since February 2015 Independent Compensation Committee member Governance and Nominating Committee member 2020 Director Compensation: Fees earned or paid in cash $62,500, Stock awards $174,999, Total $237,499
2022-04-27	Glenn R. Larsen, Ph.D. serve as Class II Directors, with terms of office expiring at this year9s Annual Meeting. Drs. Blanchard and Larsen are the Board9s nominees for election to the Board at the Annual Meeting. Each Class II Director will be elected to hold office until the 2025 Annual Meeting and until their successors are duly elected and qualified. Glenn R. Larsen, Ph.D. is a member of Compensation Committee and Governance and Nominating Committee.
2023-05-01	Glenn R. Larsen, Ph.D. - Director since February 2015, Committees: Compensation, Governance and Nominating, Age: 67. Compensation: $237,488 in 2022.
2024-06-11	Glenn R. Larsen, Ph.D. Age: 70 Director since 2015 Independent Committees: Compensation, Governance and Nominating Cash fees earned: $62,500 Stock awards: $174,980 Total: $237,480